High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma

Z. S. Pavletic, Philip Jay Bierman, Julie Marie Vose, M. R. Bishop, C. D. Wu, J. L. Pierson, J. P. Kollath, D. D. Weisenburger, A. Kessinger, James Olen Armitage

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Background: High-dose therapy followed by autologous stem-cell transplantation (autoSCT) induces complete remissions in the majority of patients with advanced B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma (B-CLL). However, the long-term utility of this therapy for B-CLL is unknown. Patients and methods: Sixteen previously treated patients with B-CLL were transplanted using autologous blood (n = 13) or bone marrow (n = 3). The median age of the patients was 49 years (range 44-60 years), and the median number of prior chemotherapy regimens was two. Patients were eligible for transplantation if they had chemosensitive disease and no morphologic evidence of malignant cells in the graft. Preparative regimens included cyclophosphamide and total-body-irradiation, with or without cytarabine, or BEAC. Results: All patients engrafted and achieved a complete remission posttransplant. Ten patients were alive at a median of 41 months (range 22-125 months), and five were disease-free. Eight patients have relapsed and six have died (three from progressive malignancy). The projected three-year overall survival, failure-free survival and relapse rates were 68%, 37%, and 56%, respectively. Conclusions: AutoSCT for advanced B-CLL is associated with a high relapse rate. Whether this therapy can prolong life or produce cures is uncertain.

Original languageEnglish (US)
Pages (from-to)1023-1026
Number of pages4
JournalAnnals of Oncology
Volume9
Issue number9
DOIs
StatePublished - Sep 1 1998

Fingerprint

Stem Cell Transplantation
B-Cell Chronic Lymphocytic Leukemia
Recurrence
Incidence
Whole-Body Irradiation
Cytarabine
Cyclophosphamide
Therapeutics
Survival Rate
Transplantation
Bone Marrow
Transplants
Drug Therapy
Survival

Keywords

  • Autologous hematopoietic stem-cell transplantation
  • Chronic lymphocytic leukemia
  • Relapse rate
  • Small lymphocytic lymphoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. / Pavletic, Z. S.; Bierman, Philip Jay; Vose, Julie Marie; Bishop, M. R.; Wu, C. D.; Pierson, J. L.; Kollath, J. P.; Weisenburger, D. D.; Kessinger, A.; Armitage, James Olen.

In: Annals of Oncology, Vol. 9, No. 9, 01.09.1998, p. 1023-1026.

Research output: Contribution to journalArticle

Pavletic, Z. S. ; Bierman, Philip Jay ; Vose, Julie Marie ; Bishop, M. R. ; Wu, C. D. ; Pierson, J. L. ; Kollath, J. P. ; Weisenburger, D. D. ; Kessinger, A. ; Armitage, James Olen. / High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. In: Annals of Oncology. 1998 ; Vol. 9, No. 9. pp. 1023-1026.
@article{519aa64fc54843139fb13dc5eb98cd98,
title = "High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma",
abstract = "Background: High-dose therapy followed by autologous stem-cell transplantation (autoSCT) induces complete remissions in the majority of patients with advanced B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma (B-CLL). However, the long-term utility of this therapy for B-CLL is unknown. Patients and methods: Sixteen previously treated patients with B-CLL were transplanted using autologous blood (n = 13) or bone marrow (n = 3). The median age of the patients was 49 years (range 44-60 years), and the median number of prior chemotherapy regimens was two. Patients were eligible for transplantation if they had chemosensitive disease and no morphologic evidence of malignant cells in the graft. Preparative regimens included cyclophosphamide and total-body-irradiation, with or without cytarabine, or BEAC. Results: All patients engrafted and achieved a complete remission posttransplant. Ten patients were alive at a median of 41 months (range 22-125 months), and five were disease-free. Eight patients have relapsed and six have died (three from progressive malignancy). The projected three-year overall survival, failure-free survival and relapse rates were 68{\%}, 37{\%}, and 56{\%}, respectively. Conclusions: AutoSCT for advanced B-CLL is associated with a high relapse rate. Whether this therapy can prolong life or produce cures is uncertain.",
keywords = "Autologous hematopoietic stem-cell transplantation, Chronic lymphocytic leukemia, Relapse rate, Small lymphocytic lymphoma",
author = "Pavletic, {Z. S.} and Bierman, {Philip Jay} and Vose, {Julie Marie} and Bishop, {M. R.} and Wu, {C. D.} and Pierson, {J. L.} and Kollath, {J. P.} and Weisenburger, {D. D.} and A. Kessinger and Armitage, {James Olen}",
year = "1998",
month = "9",
day = "1",
doi = "10.1023/A:1008474526373",
language = "English (US)",
volume = "9",
pages = "1023--1026",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma

AU - Pavletic, Z. S.

AU - Bierman, Philip Jay

AU - Vose, Julie Marie

AU - Bishop, M. R.

AU - Wu, C. D.

AU - Pierson, J. L.

AU - Kollath, J. P.

AU - Weisenburger, D. D.

AU - Kessinger, A.

AU - Armitage, James Olen

PY - 1998/9/1

Y1 - 1998/9/1

N2 - Background: High-dose therapy followed by autologous stem-cell transplantation (autoSCT) induces complete remissions in the majority of patients with advanced B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma (B-CLL). However, the long-term utility of this therapy for B-CLL is unknown. Patients and methods: Sixteen previously treated patients with B-CLL were transplanted using autologous blood (n = 13) or bone marrow (n = 3). The median age of the patients was 49 years (range 44-60 years), and the median number of prior chemotherapy regimens was two. Patients were eligible for transplantation if they had chemosensitive disease and no morphologic evidence of malignant cells in the graft. Preparative regimens included cyclophosphamide and total-body-irradiation, with or without cytarabine, or BEAC. Results: All patients engrafted and achieved a complete remission posttransplant. Ten patients were alive at a median of 41 months (range 22-125 months), and five were disease-free. Eight patients have relapsed and six have died (three from progressive malignancy). The projected three-year overall survival, failure-free survival and relapse rates were 68%, 37%, and 56%, respectively. Conclusions: AutoSCT for advanced B-CLL is associated with a high relapse rate. Whether this therapy can prolong life or produce cures is uncertain.

AB - Background: High-dose therapy followed by autologous stem-cell transplantation (autoSCT) induces complete remissions in the majority of patients with advanced B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma (B-CLL). However, the long-term utility of this therapy for B-CLL is unknown. Patients and methods: Sixteen previously treated patients with B-CLL were transplanted using autologous blood (n = 13) or bone marrow (n = 3). The median age of the patients was 49 years (range 44-60 years), and the median number of prior chemotherapy regimens was two. Patients were eligible for transplantation if they had chemosensitive disease and no morphologic evidence of malignant cells in the graft. Preparative regimens included cyclophosphamide and total-body-irradiation, with or without cytarabine, or BEAC. Results: All patients engrafted and achieved a complete remission posttransplant. Ten patients were alive at a median of 41 months (range 22-125 months), and five were disease-free. Eight patients have relapsed and six have died (three from progressive malignancy). The projected three-year overall survival, failure-free survival and relapse rates were 68%, 37%, and 56%, respectively. Conclusions: AutoSCT for advanced B-CLL is associated with a high relapse rate. Whether this therapy can prolong life or produce cures is uncertain.

KW - Autologous hematopoietic stem-cell transplantation

KW - Chronic lymphocytic leukemia

KW - Relapse rate

KW - Small lymphocytic lymphoma

UR - http://www.scopus.com/inward/record.url?scp=7844232969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7844232969&partnerID=8YFLogxK

U2 - 10.1023/A:1008474526373

DO - 10.1023/A:1008474526373

M3 - Article

VL - 9

SP - 1023

EP - 1026

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 9

ER -